# Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis

> **NCT03288584** · — · UNKNOWN · sponsor: **University of Athens** · enrollment: 60 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Inflammation

## Interventions

- **DRUG:** Tocilizumab (Actemra®)
- **DRUG:** Other biological agent
- **DRUG:** Corticosteroid and non-biological agents.

## Key facts

- **NCT ID:** NCT03288584
- **Lead sponsor:** University of Athens
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-27
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288584, "Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03288584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*